Testing a targeted radiation drug placed in the brain for glioma that came back
Original title: Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
No phase is listed, so this counts as an early test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
Doctors are testing a drug that carries radiation straight to brain tumor cells.
Who this trial is for. This trial is for adults ages 18 to 80 whose grade 3 or grade 4 glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary has grown again after first treatment. It tests a drug called [225Ac]Ac-DOTA-SP, given right at the tumor through a small tube, for up to six cycles.
Where it stands. This trial has not reported results. It is measuring how long people live and how long the tumor goes without growing. The team also watches closely for side effects. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Someone whose tumor has come back may want to know this kind of local treatment is being studied. If this sounds like your situation, you can ask your care team about it. They can help you think it through.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Being in one is not a guarantee that you will be helped. It is not a promise of a cure.
Source: ClinicalTrials.gov, October 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.